ID | 1069 |
Name of the vaccine | Boostrix |
Microbe | Bacteria |
Disease name | Tetanus (Lock Jaw) |
Name of bacteria | Clostridium tetani |
Type of vaccine | Inactivated |
Nucleic acid content | DNA |
Age | 10 years and older |
Description of the vaccine | Tetanus (reduced), Diphtheria (reduced) and Pertussis vaccine (Tdap vaccine). |
Name of the manufacturer | GlaxoSmithKline Biologicals and GSK Vaccines GmbH |
Name of the manufacturing country | Belgium and Germany |
Year of manufacture | 2005 |
Clinical Phase status | Approved |
Bacterial strain | An obligate anaerobic bacillus, which is gram positive. |
Efficacy | NA |
Vaccine formulation | Suspension for injection |
Dosage | 0.5-mL injection. Initial Dose, 5 years after the DTaP or Td vaccine. Additional dose, 9 years after the Tdap vaccine. |
Mechanism of action | Serum tetanus antitoxin level of greater than or equal to 0.1 IU/mL is protective. |
Route of administration | Intramuscular |
Indications | Not indicated in children aged younger than 10 years. |
Export | Distributed by - GlaxoSmithKline Research Triangle Park |
Approval | US FDA |
Adjuvant | Aluminium hydroxide |
Repurposing | For Diphtheria and pertussis. |
Side effects of vaccine | Pain, redness, and swelling at the injection site, increase in arm circumference, headache, fatigue and gastrointestinal symptoms. |
Post vaccination | NA |
Dose type | Single dose |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NA |
Reference | https://www.fda.gov/media/124002/download |
Other name | NA |
Additional Links | NA
|